Press-release for stocks for NVO

symbols : NVO crawled time : 21:00

save search

Novo Nordisk A/S purchases B shares worth DKK 4,886 million from Novo Holdings A/S under the 2023 share repurchase programme
Published: 2023-11-06 (Crawled : 21:00) - globenewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| 23.92% | O: -0.32% H: 1.23% C: 0.92%
repurchase

Novo Nordisk A/S - share repurchase programme
Published: 2023-11-06 (Crawled : 21:00) - globenewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| 23.92% | O: -0.32% H: 1.23% C: 0.92%
repurchase

Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis
Published: 2023-10-10 (Crawled : 21:00) - globenewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| 34.67% | O: 3.75% H: 2.82% C: 2.42%
kidney

The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight
Published: 2023-10-09 (Crawled : 21:00) - prnewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| 36.06% | O: 0.09% H: 1.41% C: 0.94%
JNJ | News | $149.12 0.82% 0.3% 7.2M

Health Technology

| -5.22% | O: 0.67% H: 0.56% C: -0.01%
SNY | News | $47.15 1.84% 1.75% 2M

Health Technology

| -14.26% | O: 0.51% H: 0.0% C: 0.0%
INCY | $51.92 -0.82% -0.83% 1.8M

Health Technology

| -8.4% | O: 0.48% H: 1.39% C: 0.51%
ALPN | $64.58 0.05% 0.03% 1.6M

Health Technology

| 451.26% | O: -1.07% H: 0.0% C: -6.9%
bleeding disease market

Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight
Published: 2023-09-26 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 77

Health Technology

| -14.76% | O: -0.69% H: 0.0% C: 0.0%
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| 36.46% | O: -0.51% H: 0.62% C: 0.42%
BSX | $68.02 1.03% 0.29% 6.5M

Health Technology

| 27.91% | O: -0.09% H: 0.72% C: -1.29%
SLN | $22.5 -0.62% -0.22% 170K

Health Technology

| 125.68% | O: -1.3% H: 2.44% C: -1.42%
SNY | News | $47.15 1.84% 1.75% 2M

Health Technology

| -14.65% | O: -0.5% H: 0.0% C: 0.0%
MESO | $5.53 6.14% 5.44% 270K

Health Technology

| -43.8% | O: 3.25% H: 1.57% C: -3.15%
IONS | $41.07 0.96% 0.97% 710K

Health Technology

| -11.26% | O: 0.99% H: 2.09% C: 0.83%
AMGN | News | $271.91 1.11% 1.12% 1.4M

Health Technology

| 1.07% | O: 1.0% H: 0.69% C: -1.01%
disease cardiovascular growth market

Diabetic Peripheral Neuropathy Market Growing at a CAGR of ~6% by 2032 | DelveInsight
Published: 2023-07-20 (Crawled : 21:00) - prnewswire.com
BMEA | $10.83 -0.18% 0.09% 490K

Professional, Scientific, and T...

| -49.04% | O: 0.71% H: 3.64% C: 0.61%
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| -23.84% | O: -0.16% H: 1.18% C: 0.88%
LLY | News | $731.33 0.69% 0.36% 1.7M

Health Technology

| 57.68% | O: 0.34% H: 0.35% C: -0.72%
VRTX | $399.92 1.43% 1.45% 1.1M

Health Technology

| 9.88% | O: 0.86% H: 0.57% C: -0.68%
APLT | $4.41 0.69% 0.68% 1.1M

Health Technology

| 221.9% | O: 1.46% H: 6.12% C: 2.88%
ALT | $7.47 8.1% 7.62% 2M

Commercial Services

| 134.91% | O: 1.57% H: 0.0% C: -2.79%
growing market diabetic

Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight
Published: 2023-07-12 (Crawled : 21:00) - prnewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| -19.06% | O: 1.7% H: 0.01% C: -0.32%
LLY | News | $731.33 0.69% 0.36% 1.7M

Health Technology

| 65.99% | O: -0.08% H: 0.46% C: -1.26%
MDGL | $213.49 0.68% 0.85% 680K

Health Technology

| -3.17% | O: 0.41% H: 3.34% C: 1.43%
LPCN | $5.07 -3.8% -2.13% 21K

Health Technology

| 14.71% | O: 0.11% H: 2.15% C: 1.02%
GALT | $3.06 -9.2% -10.31% 310K

Health Technology

| 96.15% | O: 0.64% H: 7.01% C: 5.1%
ALNY | $145.79 0.96% 0.94% 400K

Health Technology

| -27.79% | O: 0.69% H: 1.02% C: 0.29%
AKRO | $20.79 0.15% 0.14% 710K

Health Technology

| -53.85% | O: 0.78% H: 1.1% C: -0.15%
cirrhosis liver growth market

Hemophilia Market to Proliferate Immensly, Predicts DelveInsight | Key Companies to Look Out for - Pfizer, Sanofi, CSL Behring, Freeline, Genentech, Shire, Spark, Novo Nordisk, Sangamo, UBI, uniQure
Published: 2023-06-21 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 77

Health Technology

| -13.47% | O: 1.33% H: 0.0% C: 0.0%
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| -21.98% | O: -0.45% H: 0.89% C: 0.13%
LLY | News | $731.33 0.69% 0.36% 1.7M

Health Technology

| 61.44% | O: 0.44% H: 1.6% C: 0.59%
SNY | News | $47.15 1.84% 1.75% 2M

Health Technology

| -13.07% | O: 0.73% H: 0.09% C: -0.6%
companies market

Global Bleeding Disorders Treatment Market Report 2022: Industry Trends, Share, Size, Growth, Opportunities and Forecasts 2021-2027
Published: 2023-01-19 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 77

Health Technology

| -6.99% | O: -2.08% H: 0.0% C: 0.0%
TAK | News | $13.36 0.91% 0.0% 1.5M

Health Technology

| -17.53% | O: -0.19% H: 0.8% C: 0.62%
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| -10.95% | O: -0.23% H: 0.56% C: 0.55%
JNJ | News | $149.12 0.82% 0.3% 7.2M

Health Technology

| -12.04% | O: 0.34% H: 0.01% C: -0.8%
SNY | News | $47.15 1.84% 1.75% 2M

Health Technology

| -6.14% | O: -0.41% H: 0.0% C: 0.0%
treatment bleeding global report market

$9.3 Billion Worldwide Rapid Acting Insulin Industry to 2027 - Featuring Adocia, Biocon Limited and Geropharm Among Others
Published: 2022-08-23 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 77

Health Technology

| 9.06% | O: -4.66% H: 0.0% C: -1.69%
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| 17.54% | O: 1.01% H: 2.53% C: 2.2%
LLY | News | $731.33 0.69% 0.36% 1.7M

Health Technology

| 132.09% | O: 0.43% H: 1.39% C: 0.76%
SNY | News | $47.15 1.84% 1.75% 2M

Health Technology

| 13.05% | O: -1.48% H: 0.0% C: 0.0%
MNKD | $4.11 -1.68% -1.46% 1.8M

Health Technology

| 5.93% | O: -0.77% H: 4.94% C: 3.64%
rapid insulin

The Worldwide Obesity Treatment Industry is Expected to Reach $25+ Billion by 2027
Published: 2022-04-04 (Crawled : 21:00) - prnewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| 10.06% | O: 0.57% H: 1.02% C: 0.31%
MDT | $80.57 1.37% 0.0% 3.8M

Health Technology

| -28.2% | O: -1.45% H: 0.0% C: 0.0%
K S | $57.98 1.05% -0.22% 1.6M

Consumer Non-Durables

| -11.22% | O: -0.4% H: 2.2% C: 1.14%
JNJ | News | $149.12 0.82% 0.3% 7.2M

Health Technology

| -16.23% | O: -0.95% H: 0.0% C: 0.0%
BC | $84.92 1.17% 0.0% 710K

Consumer Durables

| 5.49% | O: -1.27% H: 1.16% C: -5.2%
ABBV | News | $167.89 0.89% 0.51% 3.6M

Health Technology

| 3.71% | O: 0.0% H: 2.51% C: 0.95%
treatment obesity

Novo Nordisk A/S – Share repurchase programme
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| 9.54% | O: 0.91% H: 0.0% C: 0.0%

Novo Nordisk A/S purchases B shares worth DKK 4,109 million from Novo Holdings A/S under the 2021 share repurchase programme
Published: 2021-11-05 (Crawled : 21:00) - globenewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| Email alert Add to watchlist

Novo Nordisk A/S – Share repurchase programme
Published: 2021-11-05 (Crawled : 21:00) - globenewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| Email alert Add to watchlist
s

Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021
Published: 2021-10-15 (Crawled : 21:00) - biospace.com/
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| 24.71% | O: 0.78% H: 1.5% C: 1.11%
LLY | News | $731.33 0.69% 0.36% 1.7M

Health Technology

| 208.98% | O: 0.39% H: 0.0% C: 0.0%
ALNY | $145.79 0.96% 0.94% 400K

Health Technology

| -30.34% | O: 0.34% H: 0.09% C: -0.69%
kidney

Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
Published: 2021-08-05 (Crawled : 21:00) - biospace.com/
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| 27.54% | O: 3.16% H: 1.88% C: 1.77%
LLY | News | $731.33 0.69% 0.36% 1.7M

Health Technology

| 178.63% | O: 0.31% H: 0.85% C: 0.35%
ALNY | $145.79 0.96% 0.94% 400K

Health Technology

| -20.52% | O: 0.2% H: 5.7% C: 5.5%
treatment positive results trial topline

Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder
Published: 2021-07-29 (Crawled : 21:00) - biospace.com/
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| 36.91% | O: 0.49% H: 0.26% C: -0.62%
LLY | News | $731.33 0.69% 0.36% 1.7M

Health Technology

| 196.67% | O: 0.4% H: 0.3% C: -0.88%
ALNY | $145.79 0.96% 0.94% 400K

Health Technology

| -19.94% | O: -0.01% H: 1.3% C: -0.14%
new drug alcohol use disorder fda clearance treatment fda drug application clearance

Insights on the Diabetes Injection Pens Global Market to 2027 - AstraZeneca, Biocon and Novo Nordisk Among Others
Published: 2021-05-11 (Crawled : 21:00) - prnewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| 63.48% | O: 0.73% H: 1.3% C: 1.11%
LLY | News | $731.33 0.69% 0.36% 1.7M

Health Technology

| 275.52% | O: 0.0% H: 0.46% C: -0.8%
BDX | $233.88 -0.1% 0.0% 770K

Health Technology

| -3.03% | O: -0.48% H: 1.47% C: 0.67%
AZN | News | $70.13 2.31% 2.24% 4.3M

Health Technology

| 29.63% | O: 1.15% H: 0.55% C: -0.4%
diabetes injection

Novo Nordisk A/S – Share repurchase programme
Published: 2021-04-26 (Crawled : 21:00) - globenewswire.com
NVO | News | $125.26 2.08% 0.98% 3.5M

Health Technology

| 69.13% | O: -0.42% H: 0.6% C: 0.47%
s

symbols : NVO crawled time : 21:00

save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

symbols : NVO crawled time : 21:00 save search

Gainers vs Losers

Top 10 Gainers

Your saved searches

symbols : NVO crawled time : 21:00

save search